Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish Hidradenitis Suppurativa (HS) Patients

Post Marketing Observational Study to Assess Quality of Life Changes in Swedish Patients With Moderate or Severe Hidradenitis Suppurativa (HS) After 6 Months on Adalimumab Treatment (HOPE Study)

The objective of this study is to assess quality of life (QoL), skin pain, work productivity/activity and health related problems in Swedish patients with moderate to severe HS before and after 6 months treatment with Adalimumab. Participants will be treated in accordance with normal routine clinical care.

Inclusion Criteria:

• Diagnosis of Hidradenitis Suppurativa
• Prescribed Adalimumab according to the Summary of Product Characteristics (SmPC)
• Willingness to sign and date a Patient Information/Informed Consent Form

Exclusion Criteria:

• Prior biologic treatment discontinued <6 months before the baseline visit
• Patient not able to understand the language of the provided patient questionnaires
• History of non-compliance with medication or a medical history that could enhance non-compliance with medication, as determined by the investigator